Thomas Shrader
Stock Analyst at BTIG
(3.62)
# 828
Out of 5,238 analysts
97
Total ratings
48.89%
Success rate
7.49%
Average return
Main Sectors:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STOK Stoke Therapeutics | Reiterates: Buy | $39 | $32.89 | +18.58% | 4 | May 11, 2026 | |
| ACIU AC Immune | Reiterates: Buy | $8 | $2.86 | +179.72% | 5 | May 4, 2026 | |
| NTHI NeOnc Technologies Holdings | Initiates: Buy | $15 | $5.45 | +175.23% | 1 | Apr 24, 2026 | |
| CMPS COMPASS Pathways | Reiterates: Buy | $14 | $9.91 | +41.27% | 2 | Apr 20, 2026 | |
| HROW Harrow | Reiterates: Buy | $63 | $38.23 | +64.79% | 5 | Apr 17, 2026 | |
| DRUG Bright Minds Biosciences | Reiterates: Buy | $147 | $85.50 | +71.93% | 5 | Mar 30, 2026 | |
| ABOS Acumen Pharmaceuticals | Reiterates: Buy | $8 | $2.56 | +212.50% | 5 | Mar 26, 2026 | |
| OVID Ovid Therapeutics | Reiterates: Buy | $4 | $2.80 | +42.86% | 4 | Mar 26, 2026 | |
| DNLI Denali Therapeutics | Maintains: Buy | $36 → $38 | $19.62 | +93.68% | 6 | Mar 25, 2026 | |
| NRXP NRx Pharmaceuticals | Reiterates: Buy | $25 | $3.08 | +711.69% | 4 | Mar 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $6 | $2.10 | +185.71% | 5 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $12 | $4.99 | +140.48% | 3 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $1.50 | +566.67% | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $89 | $53.01 | +67.89% | 7 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $28 | $24.26 | +15.42% | 2 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $10.11 | +87.93% | 1 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $9.86 | +62.27% | 5 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $4.11 | +289.29% | 3 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $1.73 | +420.23% | 2 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $23 | $9.22 | +149.46% | 2 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $1.82 | +394.51% | 4 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.43 | - | 3 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $9.83 | +1,934.59% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $60 | $7.69 | +680.23% | 1 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $7 | $5.69 | +23.02% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3,400 → $650 | $4.84 | +13,329.75% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.22 | +4,080.33% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.79 | +234.03% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.05 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.39 | +115.83% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $193.45 | +78.86% | 3 | Feb 21, 2019 |
Stoke Therapeutics
May 11, 2026
Reiterates: Buy
Price Target: $39
Current: $32.89
Upside: +18.58%
AC Immune
May 4, 2026
Reiterates: Buy
Price Target: $8
Current: $2.86
Upside: +179.72%
NeOnc Technologies Holdings
Apr 24, 2026
Initiates: Buy
Price Target: $15
Current: $5.45
Upside: +175.23%
COMPASS Pathways
Apr 20, 2026
Reiterates: Buy
Price Target: $14
Current: $9.91
Upside: +41.27%
Harrow
Apr 17, 2026
Reiterates: Buy
Price Target: $63
Current: $38.23
Upside: +64.79%
Bright Minds Biosciences
Mar 30, 2026
Reiterates: Buy
Price Target: $147
Current: $85.50
Upside: +71.93%
Acumen Pharmaceuticals
Mar 26, 2026
Reiterates: Buy
Price Target: $8
Current: $2.56
Upside: +212.50%
Ovid Therapeutics
Mar 26, 2026
Reiterates: Buy
Price Target: $4
Current: $2.80
Upside: +42.86%
Denali Therapeutics
Mar 25, 2026
Maintains: Buy
Price Target: $36 → $38
Current: $19.62
Upside: +93.68%
NRx Pharmaceuticals
Mar 24, 2026
Reiterates: Buy
Price Target: $25
Current: $3.08
Upside: +711.69%
Mar 10, 2026
Upgrades: Buy
Price Target: $6
Current: $2.10
Upside: +185.71%
Mar 2, 2026
Maintains: Buy
Price Target: $7 → $12
Current: $4.99
Upside: +140.48%
Feb 26, 2026
Reiterates: Buy
Price Target: $10
Current: $1.50
Upside: +566.67%
Feb 26, 2026
Maintains: Buy
Price Target: $85 → $89
Current: $53.01
Upside: +67.89%
Feb 17, 2026
Maintains: Buy
Price Target: $27 → $28
Current: $24.26
Upside: +15.42%
Jan 20, 2026
Reiterates: Buy
Price Target: $19
Current: $10.11
Upside: +87.93%
Nov 18, 2025
Reiterates: Buy
Price Target: $16
Current: $9.86
Upside: +62.27%
Nov 13, 2025
Maintains: Buy
Price Target: $15 → $16
Current: $4.11
Upside: +289.29%
Nov 10, 2025
Reiterates: Buy
Price Target: $9
Current: $1.73
Upside: +420.23%
Oct 22, 2025
Maintains: Buy
Price Target: $48 → $23
Current: $9.22
Upside: +149.46%
Oct 15, 2025
Reiterates: Buy
Price Target: $9
Current: $1.82
Upside: +394.51%
Jul 1, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.43
Upside: -
Oct 3, 2023
Initiates: Buy
Price Target: $200
Current: $9.83
Upside: +1,934.59%
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $7.69
Upside: +680.23%
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $5.69
Upside: +23.02%
Mar 28, 2023
Maintains: Buy
Price Target: $3,400 → $650
Current: $4.84
Upside: +13,329.75%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.22
Upside: +4,080.33%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $4.79
Upside: +234.03%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $4.05
Upside: -
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.39
Upside: +115.83%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $193.45
Upside: +78.86%